On October 9, 2023 Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, reported that it will present interim monotherapy data from its Phase 1/2 clinical trial evaluating HPN328 in small cell lung cancer (SCLC) and other neuroendocrine neoplasms (NEN) in a poster presentation at the European Society of Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress (ESMO) (Free ESMO Whitepaper) 2023 taking place in Madrid, Spain from October 20-24, 2023 (Press release, Harpoon Therapeutics, OCT 9, 2023, View Source [SID1234635722]). HPN328 targets delta-like ligand 3 (DLL3) and is derived from Harpoon’s proprietary Tri-specific T cell Activating Construct (TriTAC) platform designed to recruit a patient’s own immune cells to kill tumor cells.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are excited to present data from over 70 patients with multiple tumor types in HPN328 monotherapy cohorts, with an emphasis on our ongoing 1 mg priming cohorts with target doses up to 24 mg. Full enrollment of these 1 mg priming dose cohorts will be the basis for selecting our recommended Phase 2 dose(s) by the end of this year. In our poster, we will share tolerability data from all enrolled patients and preliminary response data in patients at doses above the efficacy threshold of 1.215 mg," said Luke Walker, M.D., Chief Medical Officer for Harpoon Therapeutics. "In addition to nearing completion of monotherapy dose optimization, we have recently initiated enrollment in our combination cohorts evaluating HPN328 plus atezolizumab to enable future development in early lines of therapy."
Details of the ESMO (Free ESMO Whitepaper) poster presentation are as follows:
Abstract Title: Interim Results from a Phase 1/2 Study of HPN328, a Tri-Specific, Half-Life (T1/2) Extended DLL3-targeting T-Cell Engager in Patients (pts) with Small Cell Lung Cancer (SCLC) and other Neuroendocrine Neoplasms (NEN)
Presentation Number: 698P
Session Number/Title: Developmental Therapeutics
Session Date, Time: Monday, October 23, 2023, 12:00 – 13:00 CEST
Presenter: Noura Choudhury, M.D.
Location: Hall 8
The poster will also be available on Harpoon’s website following the presentation.
For more details about the ESMO (Free ESMO Whitepaper) Annual Meeting, please visit:
View Source